The immunoproteasome inhibitor ONX-0914 reduced the Th1 and Th17 differentiation of RA-CD4+ T cells but promoted their differentiation in the Th2 and Treg direction, which is beneficial in cases of RA [139]. This evidence concerns the gene CD4 and rheumatoid arthritis.